PE20010545A1 - Uso de una composicion de inhibidores de mek para el tratamiento del dolor cronico - Google Patents

Uso de una composicion de inhibidores de mek para el tratamiento del dolor cronico

Info

Publication number
PE20010545A1
PE20010545A1 PE2000000705A PE0007052000A PE20010545A1 PE 20010545 A1 PE20010545 A1 PE 20010545A1 PE 2000000705 A PE2000000705 A PE 2000000705A PE 0007052000 A PE0007052000 A PE 0007052000A PE 20010545 A1 PE20010545 A1 PE 20010545A1
Authority
PE
Peru
Prior art keywords
alkyl
composition
treatment
pain
chronic pain
Prior art date
Application number
PE2000000705A
Other languages
English (en)
Inventor
Kevin Lee
Alistair Dixon
Robert Denham Pinnock
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PE20010545A1 publication Critical patent/PE20010545A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)

Abstract

SE REFIERE AL USO DE UNA COMPOSICION QUE COMPRENDE UN INHIBIDOR DE MEK TAL COMO DERIVADOS DEL ACIDO 4-BROMO Y 4-YODO FENILAMINOBENZHIDROXAMICO, DONDE R1 ES H, OH, ALQUILO C1-C8, ALCOXI C1-C8, HALO, TRIFLUOROMETILO, CN; R2 ES H; R3, R4, R5 SON H, OH, HALO, TRIFLUOROMETILO, ALQUILO C1-C8, ENTRE OTROS; n ES 0-4; m ES 0-1; R10 Y R11 SON H, ALQUILO C1-C8, JUNTO CON N FORMAN UN CICLO DE 3-10 MIEMBROS; R6 ES H, ALQUILO C1-C8, ENTRE OTROS; R7 ES H, ALQUILO C1-C8, ALQUENILO C2-C8, ENTRE OTROS; R6 Y R7 JUNTO CON N-O FORMAN UN CICLO DE 5-10 MIEMBROS. SON COMPUESTOS I PREFERIDOS 4-FLUORO-N-HIDROXI-2-(4-YODO-2-METIL-FENILAMINO)-BENZAMIDA, 3,4-DIFLUORO-2-(4-YODO-2-METIL-FENILAMINO)-N-(3-FURILMETOXI)BENZAMIDA, ENTRE OTROS. LA COMPOSICION PUEDE SER UTIL PARA EL TRATAMIENTO DE DOLOR CRONICO (DOLOR NEUROPATICO, DOLOR IDIOPATICO, DOLOR ASOCIADO AL ALCOHOLISMO CRONICO, DEFICIENCIA VITAMINICA, UREMIA, HIPOTIROIDISMO
PE2000000705A 1999-07-16 2000-07-14 Uso de una composicion de inhibidores de mek para el tratamiento del dolor cronico PE20010545A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14429299P 1999-07-16 1999-07-16

Publications (1)

Publication Number Publication Date
PE20010545A1 true PE20010545A1 (es) 2001-06-04

Family

ID=22507940

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000705A PE20010545A1 (es) 1999-07-16 2000-07-14 Uso de una composicion de inhibidores de mek para el tratamiento del dolor cronico

Country Status (16)

Country Link
EP (1) EP1202726A2 (es)
JP (1) JP2003504400A (es)
KR (1) KR20020012315A (es)
CN (1) CN1373660A (es)
AR (1) AR024732A1 (es)
AU (1) AU5786000A (es)
CA (1) CA2374052A1 (es)
CO (1) CO5300398A1 (es)
HU (1) HUP0202623A3 (es)
IL (1) IL147619A0 (es)
NZ (1) NZ515567A (es)
PE (1) PE20010545A1 (es)
PL (1) PL352684A1 (es)
TR (1) TR200200082T2 (es)
WO (1) WO2001005392A2 (es)
ZA (1) ZA200109907B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001273498B2 (en) 2000-07-19 2006-08-24 Warner-Lambert Company Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
IL149462A0 (en) 2001-05-09 2002-11-10 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
PT3000810T (pt) 2002-03-13 2017-10-25 Array Biopharma Inc Derivados de benzimidazole alquilado n3 como inibidores de mek
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
US7632866B2 (en) 2002-10-21 2009-12-15 Ramot At Tel Aviv University Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
ATE442847T1 (de) 2003-07-24 2009-10-15 Warner Lambert Co Benzimidazol-derivate als mek-hemmer
US7538120B2 (en) 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
CA2542012A1 (en) * 2003-10-08 2005-04-21 Teijin Pharma Limited A method for producing aminopyrrolidine derivatives and intermediate compounds
AU2004283148A1 (en) 2003-10-21 2005-05-06 Warner-Lambert Company Llc Polymorphic form of N-[(R)-2,3-Dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
PT1682138E (pt) 2003-11-19 2011-02-28 Array Biopharma Inc Inibidores heterocíclicos de mek
US7732616B2 (en) 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
WO2005051304A2 (en) 2003-11-21 2005-06-09 Array Biopharma Inc. Akt protein kinase inhibitors
TWI361066B (en) * 2004-07-26 2012-04-01 Chugai Pharmaceutical Co Ltd 5-substituted-2-phenylamino benzamides as mek inhibitors
EP1922307B1 (en) 2005-05-18 2011-12-28 Array Biopharma, Inc. Heterocyclic inhibitors of mek and methods of use thereof
EA025871B9 (ru) 2005-10-07 2017-08-31 Экселиксис, Инк. Ингибиторы mek и способы их применения
SI2054418T1 (sl) 2006-07-06 2012-02-29 Array Biopharma Inc Dihidrotieno pirimidini kot AKT protein kinazni inhibitorji
CN103288753A (zh) 2006-07-06 2013-09-11 阵列生物制药公司 作为akt蛋白激酶抑制剂的环戊二烯并[d]嘧啶
WO2008006025A1 (en) 2006-07-06 2008-01-10 Array Biopharma Inc. Dihydrofuro pyrimidines as akt protein kinase inhibitors
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
ES2703723T3 (es) 2006-12-14 2019-03-12 Exelixis Inc Métodos para usar inhibidores de MEK
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US8377937B2 (en) 2007-07-05 2013-02-19 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
WO2009006567A2 (en) 2007-07-05 2009-01-08 Array Biopharma Inc. Pyrimidyl cyclopentanes as akt protein kinase inhibitors
EP2203411B1 (en) * 2007-09-20 2016-01-06 Ramot at Tel-Aviv University Ltd. N-phenyl anthranilic acid derivatives and uses thereof
US8198279B2 (en) 2007-12-19 2012-06-12 Institute Of Cancer Research: Royal Cancer Hospital (The) Pyrido[2,3-b]pyrazin-8-substituted compounds and their use
AU2009204025B2 (en) 2008-01-09 2014-02-20 Array Biopharma Inc. Hydroxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
NZ586720A (en) 2008-01-09 2012-11-30 Array Biopharma Inc Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor
US8993630B2 (en) 2008-11-10 2015-03-31 Bayer Intellectual Property Gmbh Substituted sulphonamido phenoxybenzamides
CA2777071A1 (en) 2009-10-21 2011-04-28 Bayer Pharma Aktiengesellschaft Substituted halophenoxybenzamide derivatives
EP2491016A1 (en) 2009-10-21 2012-08-29 Bayer Pharma Aktiengesellschaft Substituted benzosulphonamides
EP2491015A1 (en) 2009-10-21 2012-08-29 Bayer Pharma Aktiengesellschaft Substituted benzosulphonamides
PL2531502T3 (pl) 2010-02-01 2014-08-29 Cancer Research Tech Ltd 1-(5-tert-Butylo-2-fenylo-2H-pirazol-3-ilo)-3-[2-fluoro-4-(1-metylo-2-okso-2,3-dihydro-1H-imidazo[4,5-b]pirydyn-7-yloksy)-fenylo]-mocznik i związki pokrewne oraz ich zastosowanie w terapii
JP2013542214A (ja) 2010-10-29 2013-11-21 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 置換フェノキシピリジン類
US9682082B2 (en) 2011-04-01 2017-06-20 Genentech, Inc. Combinations of AKT and MEK inhibitor compounds, and methods of use
PT2694072T (pt) 2011-04-01 2018-02-26 Genentech Inc Combinação de composto inibidor de akt e abiraterona para utilização em tratamentos terapêuticos
KR102204520B1 (ko) 2012-10-12 2021-01-20 엑셀리시스, 인코포레이티드 암의 치료에 사용하기 위한 화합물의 신규 제조 방법
JP6863742B2 (ja) * 2013-09-11 2021-04-21 ジ・アドミニストレーターズ・オブ・ザ・チューレーン・エデュケーショナル・ファンド 新規アントラニルアミドとその使用
GB201320732D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Methods of chemical synthesis
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
WO2017075192A1 (en) * 2015-10-27 2017-05-04 Acetylon Pharmaceuticals, Inc. Hdac inhibitors for the treatment of diabetic peripheral neuropathy
KR20200072499A (ko) 2017-10-17 2020-06-22 아트리바 테라퓨틱스 게엠베하 바이러스 및 박테리아 감염의 치료를 위한 신규한 mek-억제제
EP3989957A1 (en) * 2019-06-28 2022-05-04 University of Copenhagen Treatment of cns disorders with sleep disturbances

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5610398A (en) * 1997-02-28 1998-09-18 Warner-Lambert Company Method of treating or preventing septic shock by administering a mek inhibitor
NZ501277A (en) * 1997-07-01 2002-12-20 Warner Lambert Co -2(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
CN1163475C (zh) * 1997-07-01 2004-08-25 沃尼尔·朗伯公司 4-溴或4-碘苯基氨基苯氧肟酸衍生物及其作为mek抑制剂的用途
EP1143957A3 (en) * 1998-12-16 2002-02-27 Warner-Lambert Company Treatment of arthritis with mek inhibitors

Also Published As

Publication number Publication date
EP1202726A2 (en) 2002-05-08
AU5786000A (en) 2001-02-05
AR024732A1 (es) 2002-10-23
CA2374052A1 (en) 2001-01-25
TR200200082T2 (tr) 2002-04-22
JP2003504400A (ja) 2003-02-04
IL147619A0 (en) 2002-08-14
HUP0202623A3 (en) 2003-03-28
WO2001005392A2 (en) 2001-01-25
ZA200109907B (en) 2003-02-28
CN1373660A (zh) 2002-10-09
CO5300398A1 (es) 2003-07-31
KR20020012315A (ko) 2002-02-15
PL352684A1 (en) 2003-09-08
HUP0202623A2 (hu) 2002-11-28
NZ515567A (en) 2004-03-26
WO2001005392A3 (en) 2001-07-19

Similar Documents

Publication Publication Date Title
PE20010545A1 (es) Uso de una composicion de inhibidores de mek para el tratamiento del dolor cronico
PE20010547A1 (es) Uso de una composicion de inhibidores de mek para tratar el dolor cronico
PE20020693A1 (es) Agonistas del receptor alfa activado del proliferador de peroxisomas
PE108099A1 (es) Acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
AR097445A2 (es) Ésteres oxigenados de ácidos 4-yodo fenilamino benzhidroxámicos
PE20001539A1 (es) Composiciones farmaceuticas con agentes tiromimeticos antiobesidad
FI822943L (fi) Tromboxansyntetas-inhibitorer, processer foer deras framstaellning och farmaceutiska kompositioner innehaollande dessa
MX9603506A (es) Compuestos oxazol aromaticos, heterociclicos y sus usos.
TR200001391T2 (tr) Matris metaloproteinaz önleyicileri olarak beta-sülfonil hidroksamik asitlerin alfa-hidroksi, -amino ve halo türevleri.
DE69710204T2 (de) Alpha-amino sulfonyl hydroxamsäure als matrix metalloproteinase inhibitoren
CO5070574A1 (es) Derivado del acido fenoxiacetico y composicion farmaceutica que lo contiene
PE16299A1 (es) Compuestos de 2-imidazolinilaminoindol utiles como agonistas de alfa-2 adrenoreceptores
PE20010486A1 (es) Compuestos de acido hidroxamico utiles como inhibidores de metaloproteinasa de matriz
CO5700781A2 (es) Agonistas morfolinicos de la dopamina
ES429234A1 (es) Procedimiento para la preparacion de nuevas amidas de aci- dos n-(1-(omega-fenilalcohil)-piperidil-4)-n-(alfa-piridil)-carboxilicos.
KR950702655A (ko) 신규한 3―치환 파라―아미노페놀과 케라틴섬유 염색에 있어서 이들의 용도(Novel 3―substituted para―aminophenols and use therof in dyeing keratinous fibres)
ES8801175A1 (es) Un procedimiento para preparar derivados de fenil-tioalcanos
ES477421A1 (es) Procedimiento para la preparacion de acidos3-(2-(n-alcohil- inferior-benzamido)-fenil)-alcanoicos.
EP0235452A3 (en) Organic compounds and their pharmaceutical use
DE3864660D1 (en) Thiophen-derivate.
TR200202439T2 (tr) Sodyum hidrojen değiştirici tip 1 önleyici (NHE-1)
RS51141B (sr) Supstituisani tiofeni, postupak za njihovu proizvodnju, njihova primena u svojstvu leka, kao i lek koji sadrži ova jedinjenja
ES2165410T3 (es) Nuevas 5-(ariloxi-metil)-oxazolinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen.
GB1185334A (en) Thienobenzothiazepines
ZA839552B (en) Optionally active phenoxypropionic acid derivatives

Legal Events

Date Code Title Description
FC Refusal